Table 4.
SBRT of liver oligometastases
| |
Liver metastases (N) |
Dose (Gy × fr) |
Median follow up (mos) |
Actuarial LC rate (%) |
|
|---|---|---|---|---|---|
| at 12 mos | at 24 mos | ||||
| Herfarth et al. 2001 [40] |
56 |
14-26 × 1 |
6 |
75 |
|
| Wulf et al. 2001 [41] |
23 |
30 × 3 |
9 |
76 |
61 |
| Wulf et al. 2006 [42]. |
51 |
variable dose × (1–3) |
15 |
92 |
66 |
| Hoyer et al. 2006 [43] |
97/141*lesions |
45 × 3 |
4.3 years |
|
79 |
| Méndez-Romero et al. 2006 [44] |
34 |
37.5 × 3 |
13 |
100 |
86 |
| Kavanagh et al. 2006 [45]. |
36 |
60 × 3 |
19 |
93 (at 18 mos) |
|
| Milano et al. 2008 [46]. |
120/293*lesions |
50 × 5 |
41 |
|
67 |
| Rusthoven et al. 2009 [47]. |
63 |
36 - 60 × 3 |
16 |
95 |
92 |
| Van der Pool et al. 2010 [48] |
31 |
37.5 - 45 × 3 |
26 |
100 |
74 |
| Rule et al. 2010 [49]. |
37 |
30 × 3 |
20 |
|
56 |
| |
|
50 × 5 |
|
|
89 |
| 60 × 5 | 100 | ||||
LC: local control.
* Ratio of liver oligometastases to total number of oligometastases.